First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 771 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR High HPV Vaccination Coverage in England Associated with a Substantial Reduction in Cervical Cancer Mortality FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions MOST POPULAR Online Retailer Chastised for Claiming Their Bra Reduces Risk of Breast... June 26, 2020 Mom Of Three Fought Breast Cancer, Drought, And Australia Bushfires In... January 8, 2020 Electronic Symptom Monitoring with PROs Improves Patient-Reported Physical Function, Symptom Control,... July 6, 2022 Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer December 15, 2023 Load more HOT NEWS Coronavírus e COVID-19: o que as pessoas com câncer precisam saber Oncology Research Rebounds from Pandemic Low, but Shows Cancer Patients Need... EMA Recommends Extension of Therapeutic Indications for Darolutamide New Imaging Tool Could Predict Whether Hormone Therapy Will Work in...
